article thumbnail

Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA

The Dermatology Digest

Verrica Pharmaceuticals Inc.’s The post Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA appeared first on The Dermatology Digest. s YCANTH now has New Chemical Entity (NCE) Status and a listing in the Orange Book from the U.S. YCANTH (cantharidin) topical solution, 0.7%

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. seeking Food and Drug Administration approval for the use of YCANTH for the treatment of common warts, but may also be utilized by Verrica to seek future marketing authorizations in territories outside the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biosimilar News: Stada, Alvotech Launch the First Ustekinumab Biosimilar Across Europe

The Dermatology Digest

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

article thumbnail

There Are So Many Skincare Lines– Is One Better Than Another?

Renee Rouleau

In today’s saturated skincare market, it can be overwhelming to navigate through the countless options available. Pharmaceutical and Medical Advancements Ingredients that have been traditionally used for non-skincare purposes are now finding their way into the beauty industry. This is a fair point.

Skincare 195
article thumbnail

Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a ‘huge win’ for future sales

Aesthetics Advisor

Analysts saw the benefit extending the market for Wegovy as well as Lilly’s Mounjaro and possibly removing an obstacle in insurance reimbursement. Morgan Stanley analysts project the global obesity market will reach $77 billion in 2030; they had previously estimated $54 billion. also gained — rising 9.0% respectively. respectively.

Sales 36
article thumbnail

Meet SciBase’s New Chairman of the Board

The Dermatology Digest

Mr. Høiland has more than 25 years of experience in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US). “He will bring valuable insights and experience especially from the US market, which is our primary focus. . He will succeed Tord Lendau.

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.